Lu­ca Santarel­li’s PhI­II is good to go, he has a new app to stop Covid-19 from in­fect­ing the da­ta and $110M to pave the way

Last week
Venture

A long-haul biotech with some im­pres­sive back­ers and big goals re­cruits a ma­jor league R&D ex­ec to the helm. What’s next?

Last week
People
Startups

Roche turns to a Har­vard up­start out of George Church’s lab to con­struct AAV 2.0 mod­el vec­tors — a key part of build­ing the gene ther­a­py pipeline

Last week
Deals
Cell/Gene Tx

What are the right in­gre­di­ents for a block­buster uni­corn IPO? Nor­bert Bischof­berg­er has some thoughts on that

2 weeks ago
Bioregnum
IPOs

Af­ter re­cruit­ing an As­traZeneca vet as CEO to head a new team and rais­ing $139M cash, lit­tle Ole­ma ap­pears to be ready to launch … some­thing

4 weeks ago
Venture
IPOs

Scoop: ARCH’s Bob Nelsen is back­ing an mR­NA up­start that promis­es to up­end the en­tire man­u­fac­tur­ing side of the glob­al busi­ness

Last month
Cell/Gene Tx
Manufacturing

Sean Bo­hen's break from bio­phar­ma is over. The ex-As­traZeneca CMO has re­tired his Big Phar­ma jer­sey and is now — hap­pi­ly — run­ning a lit­tle biotech

Last month
People
Bioregnum

Here's a look at every­thing Mer­ck­'s BD group has done in the past 12 years, il­lus­trat­ing why the Seat­tle Ge­net­ics deal stands out

Last month
Deals
R&D

Arie Bellde­grun and David Chang god­fa­ther the $110M launch of a new cell ther­a­py play­er. And this one is al­so think­ing big

Last month
Startups
R&D

Scoop: Gilead’s CAR-T play­er Kite waves good­bye to re­search chief Pe­ter Em­tage as an­oth­er top ex­ec hits the ex­it

Last month
People
Cell/Gene Tx

Brent Saun­ders piv­ots from Al­ler­gan sale to a $460M SPAC, mak­ing him an overnight play­er in one of the hottest mon­ey-rais­ing gam­bits in biotech

Last month
Deals

Long­time biotech vet An­drew Hirsch is tak­ing the top job at C4 — and he clear­ly has some big plans

Last month
People
R&D

Game change: A fron­trun­ner in the cell ther­a­py 2.0 field of­fers a first look at their lead ther­a­py. And it’s a doozy

Last month
Cell/Gene Tx

A pair of Bay Area biotech up­starts with deep pock­ets and a shared in­ter­est in cu­ra­tive can­cer drugs join R&D forces

Last month
Startups
R&D

GSK, Vir bar­rel in­to a fast PhII/III for their lead Covid-19 an­ti­body, chas­ing a mov­ing tar­get with quick OK in sight

Last month
R&D
Coronavirus

Dri­ving to the $278M mark on rais­es, a leg­endary R&D ex­pert sets his sights on an­oth­er piv­otal goal line

2 months ago
People
Venture

Bris­tol My­ers bets $475M cash on a block­buster shot at break­ing the mold in im­muno-on­col­o­gy — with a po­ten­tial IL-12 game-chang­er

2 months ago
Deals

Bio­Marin CSO diss­es ri­vals for the he­mo­phil­ia A gene ther­a­py crown: Way be­hind, fac­ing big re­cruit­ment chal­lenges and at best a .6 on the gen-one scale

2 months ago
Bioregnum
Cell/Gene Tx

So Covid-19 leader BioN­Tech has a can­cer vac­cine in de­vel­op­ment? Yes, and Re­gen­eron just jumped in for the PhII com­bo study

2 months ago
Bioregnum
R&D

Af­ter Big Phar­ma aban­doned in­fec­tious dis­eases, 5 biotech con­trar­i­ans de­cid­ed to go all in. Then Covid-19 changed every­thing

2 months ago
People
Coronavirus

A wob­bly Bio­gen makes a sur­prise switch in the ex­ec­u­tive suite, trig­ger­ing a re­newed burst of M&A chat­ter

3 months ago
People

Gilead lines up a $1.55B biotech buy­out deal as CEO Dan O’Day in­vests in his lat­est can­cer block­buster dream

3 months ago
Deals

Eli Lil­ly’s mirik­izum­ab joins the club beat­ing up on Cosen­tyx as an­oth­er head-to-head study leaves No­var­tis’ drug in the dust

3 months ago
R&D

An­ti­body leg­end Till­man Gern­gross is el­bow­ing his way in­to the Covid-19 R&D cru­sade: 'I don’t see this end­ing any­time soon'

3 months ago
Startups
Bioregnum
1234 Next page Last page